Literature DB >> 15028243

Comparison of the binding of the irreversible monoamine oxidase tracers, [(11)C]clorgyline and [(11)C]l-deprenyl in brain and peripheral organs in humans.

Joanna S Fowler1, Jean Logan, Gene-Jack Wang, Nora D Volkow, Frank Telang, Yu-Shin Ding, Colleen Shea, Victor Garza, Youwen Xu, Zizhong Li, David Alexoff, Paul Vaska, Richard Ferrieri, David Schlyer, Wei Zhu, S John Gatley.   

Abstract

The monoamine oxidase A and B (MAO A and B) radiotracers [(11)C]clorgyline (CLG) and [(11)C]L-deprenyl (DEP) and their deuterium labeled counterparts (CLG-D and DEP-D) were compared to determine whether their distribution and kinetics in humans are consistent with their physical, chemical and pharmacological properties and the reported ratios of MAO A:MAO B in post-mortem human tissues. Irreversible binding was consistently higher for DEP in brain, heart, kidneys and spleen but not lung where CLG >DEP and not in thyroid where there is no DEP binding. The generally higher DEP binding is consistent with its higher enzyme affinity and larger free fraction in plasma while differences in regional distribution for CLG and DEP in brain, heart, thyroid and lungs are consistent with different relative ratios of MAO A and B in humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15028243     DOI: 10.1016/j.nucmedbio.2003.10.003

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  9 in total

Review 1.  Translational neuroimaging: positron emission tomography studies of monoamine oxidase.

Authors:  Joanna S Fowler; Jean Logan; Nora D Volkow; Gene-Jack Wang
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

2.  Mapping human brain fatty acid amide hydrolase activity with PET.

Authors:  Pablo M Rusjan; Alan A Wilson; Romina Mizrahi; Isabelle Boileau; Sofia E Chavez; Nancy J Lobaugh; Stephen J Kish; Sylvain Houle; Junchao Tong
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-05       Impact factor: 6.200

3.  PET radiopharmaceuticals for probing enzymes in the brain.

Authors:  Jason P Holland; Paul Cumming; Neil Vasdev
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

Review 4.  Neuroinflammation in Neurodegenerative Disorders-a Review.

Authors:  Martin Schain; William Charles Kreisl
Journal:  Curr Neurol Neurosci Rep       Date:  2017-03       Impact factor: 5.081

5.  Blocking of fatty acid amide hydrolase activity with PF-04457845 in human brain: a positron emission tomography study with the novel radioligand [(11)C]CURB.

Authors:  Isabelle Boileau; Pablo M Rusjan; Belinda Williams; Esmaeil Mansouri; Romina Mizrahi; Vincenzo De Luca; Douglas S Johnson; Alan A Wilson; Sylvain Houle; Stephen J Kish; Junchao Tong
Journal:  J Cereb Blood Flow Metab       Date:  2015-06-17       Impact factor: 6.200

6.  Neural mechanisms of anger regulation as a function of genetic risk for violence.

Authors:  Nelly Alia-Klein; Rita Z Goldstein; Dardo Tomasi; Patricia A Woicik; Scott J Moeller; Benjamin Williams; Ian W Craig; Frank Telang; Anat Biegon; Gene-Jack Wang; Joanna S Fowler; Nora D Volkow
Journal:  Emotion       Date:  2009-06

7.  Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.

Authors:  A Pal; A Glekas; M Doubrovin; J Balatoni; Mohammed Namavari; T Beresten; D Maxwell; S Soghomonyan; A Shavrin; L Ageyeva; R Finn; S M Larson; W Bornmann; J G Gelovani
Journal:  Mol Imaging Biol       Date:  2006 Sep-Oct       Impact factor: 3.484

8.  [11C]PBR28 radiotracer kinetics are not driven by alterations in cerebral blood flow.

Authors:  Christin Y Sander; Stefano Bovo; Angel Torrado-Carvajal; Daniel Albrecht; Hongping Deng; Vitaly Napadow; Julie C Price; Jacob M Hooker; Marco L Loggia
Journal:  J Cereb Blood Flow Metab       Date:  2021-06-23       Impact factor: 6.960

Review 9.  Potential Roles of microRNAs in the Regulation of Monoamine Oxidase A in the Brain.

Authors:  Yuki Higuchi; Tomoko Soga; Ishwar S Parhar
Journal:  Front Mol Neurosci       Date:  2018-09-14       Impact factor: 5.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.